The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome


Creative Commons License

Selma M. V. , Gonzalez-Sarrias A., Salas-Salvado J., Andres-Lacueva C., Alasalvar C., ÖREM A. , ...Daha Fazla

CLINICAL NUTRITION, cilt.37, ss.897-905, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 37 Konu: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.clnu.2017.03.012
  • Dergi Adı: CLINICAL NUTRITION
  • Sayfa Sayıları: ss.897-905

Özet

Background & aims: Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status.